Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29777009 | 1.00 | TSHR (0.41) | TSHRALDH1A1TDP1GRIN2DGRIN3B | |
| SCHEMBL28076936 | 0.87 | ALDH1A1 (0.40) | TSHRALDH1A1TDP1GRIN2DGRIN3B | |
| SCHEMBL27942931 | 0.85 | MAPT (0.41) | TSHRALDH1A1TDP1GRIN2DGRIN3B | |
| SCHEMBL29779688 | 0.85 | ALDH1A1 (0.47) | TSHRALDH1A1TDP1GRIN2DGRIN3B | |
| SCHEMBL1625178 | 0.85 | ALDH1A1 (0.47) | TSHRALDH1A1TDP1GRIN2DGRIN3B | |
| SCHEMBL5446122 | 0.81 | MAPT (0.45) | TSHRALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL26104768 | 0.81 | ALDH1A1 (0.38) | TSHRALDH1A1TDP1GRIN2DGRIN3B | |
| SCHEMBL31569520 | 0.81 | MAPT (0.45) | TSHRALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL1693396 | 0.80 | ALDH1A1 (0.54) | TSHRALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL16244909 | 0.79 | MAPT (0.49) | TSHRALDH1A1TDP1GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114835639-B | Preparation method of nevirapine intermediate | 南京红太阳生物化学有限责任公司 | 2023-12-15 | — | — | CN | claimed |
| CN-114835639-A | Preparation method of nevirapine intermediate | 南京红太阳生物化学有限责任公司 | 2022-08-02 | — | — | CN | claimed |
| US-20260062427-A1 | Bicyclic Ureas As Kinase Inhibitors | INCYTE CORP (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260049093-A1 | Bicyclic Ureas As Kinase Inhibitors | INCYTE CORP (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260042781-A1 | Bicyclic Ureas As Kinase Inhibitors | INCYTE CORP (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4646411-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250214991-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS | 2025-07-03 | — | — | US | disclosed |
| US-20250177363-A1 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-06-05 | — | — | US | disclosed |
| WO-2025101780-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | OCTANT, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| WO-2025056065-A1 | CHEMOKINE RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION, AND USE | 上海医药集团股份有限公司 | 2025-03-20 | — | — | WO | disclosed |
| EP-4499629-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | SHIMOJO MASATO | 2003-12-25 | — | — | US | disclosed |
| WO-2003086371-A2 | USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF IL-6 INVOLVED DISEASES | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | disclosed |
| EP-1326864-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | disclosed |
| EP-1326606-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | disclosed |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PFIZER PHARMACEUTICALS INC. (JP) | 2002-06-20 | — | — | US | disclosed |
| WO-2002032422-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002032900-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
| US-4068085-A | YELLOW AND RED ON POLYESTERS AND ACRYLICS | CIBA-GEIGY CORPORATION (US) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049093-A1 | Bicyclic Ureas As Kinase Inhibitors | OXSR1, JAK1, NCOR1 | TSHR 157/4885ALDH1A1 1726/4885TDP1 3277/4885 |
| US-20250177363-A1 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | TLR9, TLR3, TLR1 | TSHR 1671/4885ALDH1A1 2715/4885TDP1 280/4885 |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | TSHR 4596/4885ALDH1A1 588/4885TDP1 4486/4885 |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PTGER4, PTGER1, IL6 | TSHR 518/4885ALDH1A1 1858/4885TDP1 4244/4885 |
| US-20260042781-A1 | Bicyclic Ureas As Kinase Inhibitors | NR0B1, NR2C2, ERBB2 | TSHR 226/4885ALDH1A1 2073/4885TDP1 3704/4885 |
| US-20250214991-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | IKZF1, IKZF2, IKZF3 | TSHR 3900/4885ALDH1A1 3438/4885TDP1 2468/4885 |
| US-20260062427-A1 | Bicyclic Ureas As Kinase Inhibitors | OXSR1, NCOR1, NR0B1 | TSHR 106/4885ALDH1A1 2038/4885TDP1 3082/4885 |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PTGER4, PTGER1, PTGER2 | TSHR 351/4885ALDH1A1 1286/4885TDP1 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.